Drug Trial Radar · NCT01220492
Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
Last checked: Nov 19, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
266
Actual
Start
May 2009
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Beijing 302 HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it's serious problems. The potential for stem cells to differentiate into hepatocytes cells was recently confirmed. Particularly, autologous bone marrow-derived mesenchymal stem cell (BM-MSC) has been demonstrated to decrease MELD score and increase serum albumin in the patients with decompensated liver cirrhosis. Therefore, the investigators propose a hypothesis that umbilical cord-derived MSCs (UC-MSC) can also improve the disease conditions of LC patients, particularly reducing the decompensated conditions in these patients.
Conditions
- Liver Cirrhosis
Interventions
conventional plus MSC treatmentDrug
received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
conventional plus placebo treatmentDrug
received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- survival timeTime frame: 75 months
- incidence of HCC eventsTime frame: 75 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing 302 Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.